How should leukocytosis be evaluated and managed in a patient with malignancy after surgery?

Leukocytosis in Malignancy/Post-Surgery: Evaluation and Management

In patients with malignancy who develop leukocytosis post-surgery, immediately distinguish between reactive leukocytosis (infection, tissue injury, growth factor administration) and disease-related hyperleukocytosis, as the latter requires urgent cytoreductive therapy to prevent life-threatening leukostasis.

Critical Initial Assessment

The first priority is determining whether leukocytosis represents:

• Reactive process (infection, surgical stress, G-CSF administration)
• Underlying hematologic malignancy (previously undiagnosed or disease progression)
• Paraneoplastic phenomenon from solid tumor

Key Diagnostic Steps

Obtain peripheral blood smear immediately - this is the single most important test. Look for:

• Blast cells or immature myeloid forms (suggests acute leukemia)
• Left shift with toxic granulation (suggests infection/reactive)
• Circulating blasts >20% (acute leukemia)
• Monocytosis (consider CMML, especially post-operatively) 1

Define the degree of leukocytosis:

• WBC >100 × 10⁹/L = hyperleukocytosis, high risk for leukostasis 2, 3
• WBC 50-100 × 10⁹/L = moderate elevation, requires close monitoring
• WBC <50 × 10⁹/L = mild elevation, likely reactive unless blasts present

Management Algorithm Based on WBC Count and Clinical Context

If WBC >100 × 10⁹/L (Hyperleukocytosis)

This is a medical emergency requiring immediate intervention 2, 3:

1. Assess for leukostasis symptoms:

   • Pulmonary: dyspnea, hypoxia, pulmonary infiltrates
   • Neurologic: confusion, headache, visual changes, intracranial hemorrhage
   • Splenic infarction 1

2. Initiate cytoreduction immediately (even before definitive diagnosis if leukostasis present):

   • Hydroxyurea 50-60 mg/kg/day until WBC <10-20 × 10⁹/L 2
   • For AML with hyperleukocytosis: add idarubicin or cytarabine-based chemotherapy 2
   • Avoid leukapheresis - no proven survival benefit and may precipitate hemorrhage in APL 4

3. Supportive measures:

   • Aggressive hydration (but avoid excessive RBC transfusions - increases viscosity)
   • Allopurinol or rasburicase for tumor lysis syndrome prevention 2
   • Monitor urine pH and electrolytes closely
   • Avoid invasive procedures until WBC controlled 4

If WBC 50-100 × 10⁹/L

Urgent evaluation required:

• If blasts present on smear: treat as hyperleukocytosis above
• If post-operative with solid tumor history: consider paraneoplastic leukemoid reaction 5
• If recent G-CSF administration: likely drug-induced, monitor closely 6

For post-operative leukocytosis specifically:

• CMML can present with post-operative hyperleukocytosis and leukostasis 1
• Requires bone marrow biopsy and cytogenetics for diagnosis
• Rapid institution of hydroxyurea critical to prevent morbidity/mortality 1

If WBC <50 × 10⁹/L

Differentiate reactive from malignant:

Reactive leukocytosis (most common post-surgery):

• Neutrophil predominance with left shift
• No blasts or dysplastic features
• Resolves with treatment of underlying cause
• Do not treat with cytoreduction 7

Chronic lymphocytic leukemia (CLL):

• Lymphocyte predominance
• Absolute lymphocyte count alone is NOT an indication for treatment 8
• Only treat if symptomatic (cytopenias, bulky adenopathy, constitutional symptoms)
• Leukostasis rarely occurs in CLL despite high counts 8

Chronic myeloid leukemia (CML):

• Symptomatic leukocytosis: hydroxyurea, apheresis, or imatinib 7
• Symptomatic thrombocytosis: hydroxyurea, anti-aggregants, anagrelide 7

Specific Malignancy Considerations

Acute Promyelocytic Leukemia (APL)

If WBC >10 × 10⁹/L at presentation or rising after ATRA initiation 4:

• Start cytoreductive chemotherapy immediately (idarubicin 12 mg/m² or gemtuzumab ozogamicin 6-9 mg/m²)
• Never perform leukapheresis - fatal hemorrhage risk 4
• Prophylactic corticosteroids may reduce differentiation syndrome risk 4

Solid Tumors with Leukocytosis

• Paraneoplastic leukemoid reactions occur in 3% of hyperleukocytosis cases, predominantly with advanced solid tumors 9
• Pancreatic cancer particularly associated with aggressive leukemoid reactions 5
• Poor prognosis; treatment directed at underlying malignancy
• Cytoreduction (hydroxyurea) for symptomatic relief only

Common Pitfalls to Avoid

1. Assuming all post-operative leukocytosis is reactive - CMML can present this way 1
2. Transfusing RBCs aggressively in hyperleukocytosis - increases blood viscosity and worsens leukostasis 2
3. Using leukapheresis in APL - precipitates fatal hemorrhage 4
4. Treating CLL based on lymphocyte count alone - symptoms, not numbers, guide therapy 8
5. Delaying peripheral smear review - this is diagnostic and must be done immediately 9

When to Consult Hematology Urgently

• Any WBC >100 × 10⁹/L
• Blasts present on peripheral smear
• Symptoms of leukostasis (respiratory distress, neurologic changes)
• Post-operative leukocytosis with monocytosis (CMML concern)
• Unexplained persistent leukocytosis >50 × 10⁹/L despite treating infection

The key principle: hyperleukocytosis with blasts is a hematologic emergency requiring immediate cytoreduction, while reactive leukocytosis requires only treatment of the underlying cause. The peripheral blood smear distinguishes these within minutes and should never be delayed.